Skip to Content
Merck
All Photos(2)

Key Documents

More Documents

14701C

SAFC

EX-CELL® Glycosylation Adjust (Gal +)

protein quality supplement

Pharma Manufacturing

Synonym(s):

N-linked glycosylation reagent

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12352207
NACRES:
NA.75

Quality Level

500

form

liquid

quality

GMP
chemically defined

technique(s)

cell culture | mammalian: suitable

impurities

Sterility Tested, pH, Endotoxin, and Appearance

suitability

suitable for manufacturing use

storage temp.

2-8°C

Related Categories

General description

A protein quality supplement that targets glycosylation attributes, EX-CELL® Glycosylation Adjust (Gal+) allows users to easily and quickly achieve desired N-linked glycosylation by increasing the galactose site occupancy on the oligosaccharide to a higher level. Supplementation demonstrates 2- to 4-fold increases in G1F and G2F distributions when compared to processes without addition of the product. The product can be used with a broad range of cell lines, is scalable, and is regulatory friendly.
GMP concentrated solution. Intended as a cell culture supplement. Recommended titration starting point, % volume/volume.

Packaging

14701C-100ML
14701C-1000ML

Linkage

Submit the EX-CELL Glycosylation Adjust (Gal +) request form to get in touch with a SAFC representative.

Legal Information

EX-CELL is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

EX-CELL® Glycosylation Adjust (GAL+)

SAFC’s new protein quality supplement, EX-CELL® Glycosylation Adjust (Gal+), provides customers with a novel chemically defined product which targets glycosylation attributes.

Speeding Biosimilar Development using Glycosylation Control Technology from SAFC

The biosimilar market is expected to grow rapidly in the coming years, as many blockbuster monoclonal antibodies lose patent protection by 2020.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service